The 23rd company to list on this market in 2016
The Coordination and Admissions Committee of the MAB has submitted to the Board of Directors a favourable report on Pangaea Oncology,stating that the company is eligible for admission to the market, following a review of all the information presented by the company.
The company - the 23rd to list on the Mercado Alternativo Bursátil (MAB) in 2016 - is scheduled to start trading on 29 December, pending the approval by the Board of MAB. Together with the listing, the company has carried out a €3.8 million capital increase, bringing its initial market capitalisation to €28.6 million. The starting price will be €2.70 per share.
The company’s trading code will be “PANG” and trading will be through a price setting mechanism, which will match buy and sell orders by means of two daily auction periods or “fixings”. Impulsa Capital is acting as Registered Adviser and Bankinter Securities as Liquidity Provider.
Pangaea Oncology is a medical services company focused on precision oncology (personalised medicine in oncology, based on the genetics of people). The high quality of its medical praxis is supported by two fundamental pillars: the multidisciplinary medical and scientific team as well as a state-of-the-art molecular diagnosis laboratory and in-house technology.
The Informative Document of Pangaea Oncology is available on MAB’s website (www.bolsasymercados.es/mab), where all the information about the company and its activities can be found.